CTGF as target for the therapy of diabetic nephropathy

Details for Australian Patent Application No. 2005212371 (hide)

Owner FibroGen, Inc.

Inventors Oliver, Noelynn A.; Flyvbjerg, Allan; Wang, Qingjian; Liu, David Y.; Guo, Guangjie; Neff, Thomas B.; Usinger, William R.

Agent FB Rice

Pub. Number AU-B-2005212371

PCT Pub. Number WO2005/077413

Priority 60/544,121 11.02.04 US; 60/620,802 20.10.04 US; 60/578,401 09.06.04 US; 60/561,018 08.04.04 US

Filing date 11 February 2005

Wipo publication date 25 August 2005

Acceptance publication date 13 May 2010

International Classifications

A61K 31/00 (2006.01)

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 16/22 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

28 September 2006 PCT application entered the National Phase

  PCT publication WO2005/077413 Priority application(s): WO2005/077413

13 May 2010 Application Accepted

  Published as AU-B-2005212371

9 September 2010 Standard Patent Sealed

6 September 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005212372-Reversible multi lumen catheter

2005212370-Glycine and/or for use in cartilage affecting conditions